OriBase Pharma is an international CRO specialized in the design and chemistry synthesis of kinase inhibitors, and dedicated to accelerating drug discovery processes. Our technologies are based on a unique combination of rational in silico drug design & medicinal chemistry services. OriBase Pharma is involved in all drug discovery stages from hit identification to lead optimization and delivery of new drug candidates in a quick and cost effective manner. OriBase Pharma has worked on a wide range of therapeutic target classes and has a specific expertise in kinase inhibitors design. With our innovative approach and proprietary platform, we successfully design and develop new drug candidates, particularly for cancer and autoimmune diseases. OriBase Pharma offers a unique technology platform to accelerate drug discovery R&D processes - HitFast Discovery®. HitFast Discovery® consists of four proprietary technologies: SARA, MedChem Decision, EZ Design®, and ChemBase®.